Welcome to our dedicated page for Avivagen news (Ticker: VIVXF), a resource for investors and traders seeking the latest updates and insights on Avivagen stock.
Avivagen Inc. (VIVXF) is a biotechnology innovator developing science-backed solutions for animal health through its proprietary OxC-beta™ technology. This dedicated news hub provides investors and industry professionals with essential updates on Avivagen's progress in creating non-antibiotic alternatives for livestock and companion animal nutrition.
Access authoritative reports on product developments, regulatory milestones, and strategic partnerships. Our curated feed includes verified announcements about clinical trial results, manufacturing expansions, and peer-reviewed research validating Avivagen's immune-support technologies.
Key updates cover three critical areas: scientific advancements in carotenoid-based solutions, commercial partnerships with global agriculture leaders, and regulatory progress across international markets. Each news item is vetted for relevance to long-term investors tracking sustainable alternatives in animal nutrition.
Bookmark this page for streamlined access to Avivagen's official communications and third-party analyses. Check regularly for developments shaping the future of antibiotic-free animal health solutions across pork, poultry, and dairy production systems worldwide.
Avivagen Inc. (VIVXF), a life sciences company, will present at the LD Micro Conference on June 10 at 10:30 A.M. CEO Kym Anthony will represent the company. This virtual event, held from June 8-10, includes around 180 companies and various keynote speakers. Avivagen focuses on developing products that enhance immune function in livestock and companion animals, notably through OxC-beta™ technology, which offers a non-antibiotic alternative to improve health and growth. The product is available in multiple countries, demonstrating effective results compared to traditional antibiotics.
Avivagen Inc. (VIVXF) seeks TSX Venture Exchange approval to extend the expiration date for 2,029,250 warrants originally set for June 30, 2021, to January 28, 2022, at an exercise price of $1.20 per share. Additionally, the Board approved 200,000 options for an officer at a strike price of $0.50 per share. Avivagen focuses on developing products that enhance immune function for livestock and companion animals, using its proprietary OxC-beta™ technology. The company aims to replace antibiotics in livestock feeds.
Avivagen Inc. (OTCQB: VIVXF) reported its Q2 2021 financial results, achieving significant milestones including record-setting orders, an 18-month recurring contract for OxC-betaTM Livestock in Mexico, and successfully closing a $7.5 million oversubscribed unit offering. Revenue rose to $159,614 from $29,625 a year prior, though comprehensive loss increased to $(2,197,649). The company noted a substantial rise in working capital, enabling inventory investments for future sales. Avivagen continues to expand its product offerings into human consumption with the launch of Dr. Tobias Beta Blend on Amazon.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has terminated its sales and distribution agreement with CSA Animal Nutrition in the U.S. This decision comes as demand for Avivagen's OxC-betaTM Livestock product rises in Asia and Mexico. CEO Kym Anthony noted the company's intent to replicate this success in the U.S. market. The U.S. represents 18% of the global livestock feed market, producing 215 million tonnes in 2020. Avivagen's OxC-beta™ technology is a non-antibiotic alternative to traditional livestock feed antibiotics, which may fulfill global mandates to remove in-feed antibiotics.
Avivagen Inc. (VIVXF) has received its first purchase order from a leading livestock producer in Thailand following successful trials over the past nine months. This order, though modest, is expected to pave the way for wider adoption of Avivagen's OxC-beta™ Livestock product, which has shown superior performance compared to competitors. With 21 million tonnes of livestock feed produced annually in Thailand, this marks a significant market opportunity, especially as the EU has banned antibiotics as growth promoters since 2010.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has secured its largest single purchase order for 4.4 metric tonnes of OxC-beta™ Livestock from UNAHCO, marking a 10% increase over previous orders. This order reflects UNAHCO's sustained adoption of OxC-beta™ in swine and poultry, indicating strong market value. The company's technology offers a non-antibiotic alternative for livestock feed, promoting health and growth. OxC-beta™ Livestock is available in multiple countries, aiming to replace in-feed antibiotics.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) is set to issue 3,931 common shares at $0.58 each to cover a $2,280 maintenance fee on debentures from April 2019. This follows a previous issuance to cover $107,560 owed for annual fees related to 10% secured debentures. The company can opt for cash or share payments as per the debenture terms. Avivagen focuses on developing products for livestock, companion animals, and humans that enhance immune function and promote health, emphasizing its OxC-beta™ technology as a non-antibiotic alternative in animal feeds.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announced the issuance of 3,931 common shares at $0.58 each to cover a $2,280 maintenance fee for debentures from April 2019. This follows a previous announcement regarding $107,560 owed to holders of 10% secured debentures. Avivagen can choose to pay these fees in cash or shares. Avivagen specializes in developing products for livestock and companion animals that support immune function without the use of antibiotics, contributing to safer health practices in agriculture.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announced that at its Annual General Meeting (AGM), shareholders supported all resolutions, including the election of directors and reappointment of McGovern Hurley LLP as auditor. Key voting results include Kym Anthony receiving 96.6%, Graham Burton 96.7%, Aubrey Dan 97.4%, David Hankinson 96.7%, Jeffrey Kraws 97.3%, and Paul Mesburis 97.4% of votes cast in favor. Avivagen develops health products for livestock and companion animals, leveraging its OxC-beta™ technology for non-antibiotic health support.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has received approval from the TSX Venture Exchange to extend the expiry date of certain outstanding warrants. Initially set to expire on March 31, 2021, these warrants allow for the purchase of 2,774,991 common shares at $0.90 each, with the new expiry date set for June 1, 2021. All other terms remain unchanged. This approval follows the Corporation's earlier announcement on March 5, 2021, regarding its intention to extend these warrants.
